TRCT
PTHS

Tower Research Capital (TRC)’s Pelthos Therapeutics PTHS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79K Buy
+205
New +$5.26K ﹤0.01% 4259
2025
Q4 		– Sell
-827
Closed -$23.2K – 5687
2025
Q3 		$23.2K Buy
827
+818
+9,089% +$19.9K ﹤0.01% 3176
2025
Q2 		$107 Sell
9
-248
-96% -$2.99K ﹤0.01% 5141
2025
Q1 		$3.64K Buy
257
+232
+928% +$3.97K ﹤0.01% 4374
2024
Q4 		$162 Sell
25
-1
-4% -$7 ﹤0.01% 5406
2024
Q3 		$184 Buy
26
+25
+2,500% +$244 ﹤0.01% 5439
2024
Q2 		$8 Buy
+1
New +$17 ﹤0.01% 5604

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Tower Research Capital (TRC)'s PTHS Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Pelthos Therapeutics (PTHS) in Q2 2026: 205 shares worth $5.79K. The stake represents ﹤0.01% of the portfolio and ranks #4259 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in PTHS as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in PTHS in Q2 2024 and has held it in 7 quarters since. The position peaked at $23.2K in Q3 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Tower Research Capital (TRC) held 205 shares of Pelthos Therapeutics worth $5.79K as of Q2 2026.
  • Pelthos Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Pelthos Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4259 holding.
  • Tower Research Capital (TRC) first reported a position in Pelthos Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Pelthos Therapeutics position peaked at $23.2K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.